Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > My Weekly Reading for April 6, 2025
Economy

My Weekly Reading for April 6, 2025

Last updated: April 6, 2025 10:06 pm
Share
My Weekly Reading for April 6, 2025
SHARE

 

by Richard Gunderman, Law & Liberty, April 1, 2025.

Excerpt:

I must admit, I never imagined outright fraud would infiltrate the scientific community to the extent it has. While the Lancet—a paragon of medical journalism—infamously published a paper that falsely linked the measles, mumps, and rubella (MMR) vaccine to childhood autism, I believed such egregious lapses in editorial integrity and scientific honesty were anomalies. Alas, it seems I was overly optimistic.

Recent revelations indicate that a staggering proportion of scientific studies are not reproducible, with a notable fraction being outright fraudulent. This troubling trend has given rise to dedicated scientists who are now on a quest to unearth deficient or deceptive research. A prime resource in this battle is the website Retraction Watch, which meticulously tracks and reports on the retraction of papers deemed too flawed to be credible. Such retractions serve as crucial warnings that certain findings should be approached with skepticism or outright disregarded.

 

by Zachary Caverly, Reason, April 1, 2025.

Excerpt:

In the pre-NIH era, U.S. biomedical science flourished with considerable private funding, and while proponents of increased public expenditures argue it bolstered an already solid foundation, the actual influence of government investments on landmark research is often exaggerated. Take the Human Genome Project, for instance. While the NIH proudly proclaims this monumental endeavor transformed the scientific workforce, it was the innovative automatic gene sequencer—a brainchild of Leroy Hood—that made it all possible. Ironically, Hood’s invention received some of the most dismal reviews from the NIH.

It was the philanthropic efforts of Sol Price, founder of warehouse superstores, that ultimately brought this technology to life, allowing the human genome to be sequenced. Similar narratives of private benefaction overshadowing government grants can be found in the realm of stem cell research.

Consider the case of mRNA vaccine development: The NIH timeline suggests that years of government-funded HIV research was pivotal in this breakthrough technology. However, the lead innovator, Katalin Karikó, faced numerous hurdles in academia and even suffered demotion due to her inability to secure grants. Her eventual departure to BioNTech, where she contributed to the Pfizer vaccine, is glaringly absent from the NIH’s narrative.

 

See also  NexPoint Residential raises quarterly dividend 3.9% to 53c per share

by Ronald Bailey, Reason, April 1, 2025.

Excerpt:

A recent ruling by a federal district court has championed medical innovation and patient rights, overturning the FDA’s misguided attempt to regulate laboratory-developed tests (LDTs) and in vitro diagnostics.

LDTs are diagnostic tests crafted, manufactured, and executed by individual labs, capable of diagnosing conditions and informing treatment through the detection of biomarkers in blood, saliva, or tissue. These tests can indicate risks for diseases like Alzheimer’s disease, identify cancers, and guide breast cancer treatment.

In May, the FDA introduced sweeping regulations targeting these tests for the first time. This is the same agency that infamously bungled COVID-19 testing protocols back in 2020, leading to chaos as the pandemic unfolded.

As I previously reported, out of billions of tests administered each year, the FDA attempted to justify its heavy-handed oversight by citing a handful of problematic medical device reports and unverified claims—specifically, nine and four different tests respectively—between 2009 and 2023. The majority of issues pointed to by the FDA involved tests that had already been submitted for evaluation and subsequently rejected or modified as necessary.

 

Excerpt:

The 2025 EdChoice Friedman Index serves as a straightforward metric for assessing the availability of private K–12 educational options across the United States. Drawing inspiration from Milton and Rose Friedman’s vision of universal educational choice, the index evaluates how effectively each state allows families to allocate education funding towards their preferred schools, whether public or private.

Since 2020, there has been a notable surge in educational choice initiatives nationwide. Fourteen states have been classified as offering “universal choice,” yet many of these states impose restrictions that limit accessibility due to funding caps. The EdChoice Friedman Index aims to illuminate the true extent of educational choice available to families.

See also  America is a manufacturing powerhouse

Note: The omission of any discussion regarding Trump’s tariffs does not imply endorsement. Several economists are addressing this topic with clarity, making it easy for readers to find relevant commentary on platforms like EconLog and others. I will provide additional insights on this matter next week.

TAGGED:AprilReadingWeekly
Share This Article
Twitter Email Copy Link Print
Previous Article Global stocks tumble as Donald Trump offers no respite from tariffs Global stocks tumble as Donald Trump offers no respite from tariffs
Next Article On the “Reciprocal” Tariff Plan On the “Reciprocal” Tariff Plan
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Indianapolis Colts: “I am heartbroken”

Indianapolis Colts owner Jim Irsay tragically passed away at the age of 65 on Wednesday…

May 21, 2025

The Seattle Glass Experience Returns This October

Seattle is gearing up for an exciting weekend full of colorful events as Refract: The…

September 21, 2025

Democrat in New Jersey Governor’s Race Changes Story About Naval Academy Cheating Scandal Again-Classmates Aren’t Buying It  | The Gateway Pundit | by Margaret Flavin

According to a report by The Gateway Pundit, Rep. Mikie Sherrill (D-NJ), a candidate vying…

October 15, 2025

Tennis bends to the wind’s will at Indian Wells as desert weather blows players off course

Indian Wells, California, is known for its tennis paradise, but it also brings Old Testament…

March 8, 2025

‘Bachelor in Paradise’ Boss on Season 10 Changes, Goldens Mixing With Younger

They bring a different perspective to the show, which adds an interesting dynamic to the…

July 7, 2025

You Might Also Like

3 Must-Buy Stocks Fueling the Data Center Surge
Economy

3 Must-Buy Stocks Fueling the Data Center Surge

October 31, 2025
Shake Shack returns to profit in Q3 2025
Economy

Shake Shack returns to profit in Q3 2025

October 31, 2025
Fresnillo signs agreement to acquire Probe Gold for 8m
Economy

Fresnillo signs agreement to acquire Probe Gold for $558m

October 31, 2025
Market analysts react to Trump-Xi meet
Economy

Market analysts react to Trump-Xi meet

October 31, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?